The Cancer Genome Atlas Research Network, a collaboration between two National Institutes of Health groups, has identified new drug targets for bladder cancer that invades the bladder’s muscle, a condition the group notes is the deadliest form of the disease, and for which there is no approved second-line therapy.
Researchers also found that the cancer has some genetics in common with some breast, lung, and head & neck cancers, which could help identify new ways to approach the disease.
Among the findings:
- Recurrent mutations in 32 genes, nine of which were not previously known to be “significantly mutated”
- Potential drug targets in 69% of the evaluated tumors
